Dov Grossman is a trial lawyer with over 15 years of experience focused on biopharmaceutical patent disputes, including as lead counsel.  Dov’s educational background is in chemistry, with an emphasis on medical chemistry, and he has relied on that experience to successfully represent innovator pharmaceutical companies in a wide variety of patent disputes, including for multiple billion-dollar products.  Dov has successfully tried numerous Hatch-Waxman cases, and has handled patent disputes between innovator companies.  Dov also has represented innovator companies in inter partes review proceedings involving pharmaceutical and biotech patents.

In addition, Dov has litigated matters in the medical device and telecommunications industries, and has advised clients on the negotiation of licensing agreements, including as the lead outside attorney handling the negotiations.

Dov currently serves as a member of the firm’s Associate Evaluation Committee.

Dov, who speaks Hebrew as well as English, grew up in Los Angeles.  Dov earned his J.D., with honors, from the University of Chicago, where he was articles editor for The University of Chicago Law Review and a member of the Order of the Coif.  Dov clerked for Judge William C. Bryson of the U.S. Court of Appeals for the Federal Circuit.  He received his A.B. in chemistry, magna cum laude, from Harvard University in 1997, and an M.Sc. in chemistry from the Weizmann Institute of Science in 1999.  Aspects of his Weizmann research were published in Letters in Peptide Science in 2002 (“Potentiating Vanadium-Evoked Glucose Metabolism by Novel Hydroxamate Derivatives”).  Dov joined Williams & Connolly in 2004.

Representative Experience

  • Co-lead trial counsel in a Hatch-Waxman trial in the District of Delaware relating to Bayer’s erectile dysfunction medication vardenafil (marketed as Levitra® and Staxyn®).  The Court issued a decision in favor of Bayer on its compound patent at the close of trial.
  • Trial counsel for four Hatch-Waxman trials related to Eli Lilly’s Alimta® product, three on behalf of Lilly and one on behalf of Princeton University and Lilly, each of which was decided in favor of the patentee.  Dov has also litigated multiple inter partes review proceedings related to Alimta®, resulting in two final written decisions of the Patent Trial and Appeals Board upholding validity.
  • Trial counsel for Bayer in a Hatch-Waxman case involving the factor Xa inhibitor Xarelto®, which resulted in a judgment in favor of Bayer that was not appealed.  Dov was also lead counsel in two sets of inter partes review challenges to patents protecting Xarelto®, both of which were resolved in Bayer’s favor—in one set of proceedings, the petitions were withdrawn after Bayer submitted its preliminary responses, and in the other proceeding the Board denied institution.
  • Counsel for AstraZeneca in litigation and co-pending inter partes review proceedings related to anti-diabetes treatments.
  • Trial counsel for two Hatch-Waxman trials related to moxifloxacin, the antibiotic active ingredient in Bayer’s Avelox® product and Alcon’s Vigamox® eye drops.  Both cases were resolved in favor of the patentee.
  • Counsel for Eli Lilly, Daiichi Sankyo, and Ube Industries in Hatch-Waxman litigation and co-pending inter partes review proceedings involving the anti-platelet medication Effient®.
  • Representing a client in a major international patent licensing arbitration, which was tried before a three-member panel.
  • Lead outside counsel negotiating a portfolio cross-license agreement between suppliers of electronics components.
  • Counsel for Bayer in multiple Hatch-Waxman cases involving the anti-cancer medication Stivarga® and the anti-cancer medication Nexavar®.
  • Counsel for Alcon in Hatch-Waxman litigation involving Travatan Z® eye drops.




back to top